News

Analysts Adjust Synopsys Earnings Expectations Before Q3 Release

Analysts Adjust Synopsys Earnings Expectations Before Q3 Release

Analysts Update Expectations for Synopsys, Inc. Earnings

Synopsys, Inc. (NASDAQ: SNPS) is gearing up for its earnings announcement for the third quarter of fiscal year 2025. This event is projected to take place after the close of trading on an upcoming Tuesday.

Quarterly Earnings Predictions

Financial analysts have expressed optimism, estimating that Synopsys will report earnings of approximately $3.75 per share. This figure represents a notable increase from the $3.43 per share reported during the same quarter of the previous year.

Projected Revenue Growth

In addition to earnings, analysts also anticipate an increase in revenue. Synopsys is expected to generate around $1.77 billion in quarterly revenue. This forecast reflects a growth compared to the $1.53 billion recorded in the same period last year, indicating an encouraging upward trend for the company.

Recent Developments in AI Technology

On September 3, the company made headlines by unveiling significant enhancements to its Artificial Intelligence (AI) capabilities, which are integrated into its Electronic Design Automation (EDA) solutions. This development underscores the company's commitment to leveraging AI to improve its product offerings.

Current Stock Performance

Following the announcement of its advancements in AI technology, Synopsys’ shares experienced a positive market reaction, rising by 1.8% to reach a closing price of $609.08. This reflects investor confidence in the company's strategic direction and growth potential.

Analyst Ratings Overview

Considering an investment in Synopsys? Here’s a snapshot of the latest analyst ratings:

  • Keybanc analyst Jason Celino has maintained an Overweight rating and revised the price target from $610 to $660, demonstrating confidence in Synopsys’ growth trajectory.
  • Rosenblatt analyst Blair Abernethy holds a Buy rating, lifting the price target from $625 to $650.
  • Piper Sandler analyst Clarke Jeffries keeps an Overweight rating while boosting the price target from $615 to $660.
  • B of A Securities analyst Vivek Arya has reaffirmed a Buy rating, elevating the price target from $575 to $625.
  • Needham analyst Charles Shi has also maintained a Buy rating, increasing the price target from $650 to $660 as market conditions continue to favor Synopsys.

Conclusion and Future Outlook

As the earnings announcement approaches, market observers are keenly evaluating Synopsys’ strategies and performance metrics. Analysts’ positive outlook coupled with the company’s robust advancements in technology suggest a strong competitive advantage in the industry.

Frequently Asked Questions

What are analysts predicting for Synopsys' Q3 earnings?

Analysts expect Synopsys to report earnings of $3.75 per share, an increase from $3.43 year-over-year.

What is the expected revenue for Synopsys in Q3?

Projected revenue for Synopsys in Q3 is $1.77 billion, up from $1.53 billion from the previous year.

How did Synopsys stock perform recently?

Synopsys shares rose by 1.8% to close at $609.08, reflecting positive market sentiment following AI capabilities enhancements.

Which analysts have revised their ratings for Synopsys recently?

Analysts from Keybanc, Rosenblatt, Piper Sandler, B of A Securities, and Needham have recently updated their ratings and price targets for Synopsys.

What recent developments did Synopsys announce?

Synopsys recently announced the expansion of its AI capabilities integrated within its leading EDA solutions.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

HERVolution's HERV-K Antigens: A Cancer Breakthrough?

Updated Category News Views 120

Digging into HERVolution's Game-Changing Data Picture HERVolution in the spotlight, rolling out data that could shake up our approach to cancer immunotherapy. The big headline? HERV-K antigens might just be the whistle-blower we've been looking for to get the immune system off the bench and onto the field. How's that for a kick in the conventional wisdom of cancer...

Continue Reading
DAR Logs Massive 587,000 Service Hours Nationwide

Updated Category News Views 92

A Month of Patriotism and Service You've got to hand it to the Daughters of the American Revolution (DAR)—when they commit, they go all in. This year, they turned their usual Day of Service into a full-blown Month of Service, packing in over 587,000 hours of volunteering nationwide. From historic spots to food pantries, DAR members showed up, and honestly, it's the kind...

Continue Reading
Landis+Gyr's Q2 Gains and Future Strategies

Updated Category News Views 0

Landis+Gyr's Multi-Faceted Financial Leap In the unpredictable landscape of energy tech, Landis+Gyr has thrown down some noteworthy cards in their latest financial disclosures. We're talking a Q2 net revenue sitting pretty at $269.2 million, and it's no mistake they landed a record-smashing adjusted gross margin of 38.0%. All this while wrangling an order intake of $170.3...

Continue Reading
Casio's CMK?100: A Lightweight Marvel Blending Style and Utility

Updated Category News Views 77

A Timepiece That Redefines Everyday Elegance There's a new player in the vast realm of watches, and it's got tongues wagging: the Casio CMK?100. You don’t see that blend of style, comfort, and practicality grow on trees, my friend. Casio’s new offering, the CMK?100, wears its purpose on its titanium sleeve: lightweight and stylish, it’s a suave addition to any wrist...

Continue Reading
Yale's $10M Inflammation Initiative: Future Health Impact

Updated Category News Views 25

Yale’s Inflammation Research: Beyond the Basics Inflammation. It’s the kind of battle your own body wages from within, and Yale School of Medicine’s fresh $10 million grant from the Blavatnik Family Foundation means they’re marching deeper into the trenches. This is not another academic exercise; it’s about digging out the roots of diseases that are tough to pin...

Continue Reading
MPLX Adds Industry Veterans to Board Leadership

Updated Category News Views 38

A New Era for MPLX's Board Nothing shakes up the scene like announcing two heavyweights joining the board, and that's exactly what MPLX LP (NYSE: MPLX) just pulled off. Micheal G. Dunn and Bruce L. Niemeyer are coming onboard, effective November 1, 2026. With pedigrees that could make any industry insider nod in approval, these guys bring decades of experience to the...

Continue Reading
7-Eleven Rolls Out Korean Flavors in Bold Menu Shift

Updated Category News Views 155

7-Eleven's New Global Menu Twist October 2026 sees 7-Eleven, Inc. whip out an intriguing move, venturing east with its new Flavors of Korea menu. They're not just changing the game in convenience store aisles; they're dancing to the beat of global flavors—a shake-up fit for the world's largest convenience retailer. Think about bodega basics getting a spicy Korean...

Continue Reading
From Missouri to Market: A New Spin on Turkey Calls

Updated Category News Views 24

Innovating the Turkey Call Game You want innovation? Well, wrap your head around this: a Missouri inventor is flipping the script on turkey mouth calls. The goal? To ditch the wrinkles and make turkey hunting that much smoother. It might seem a bit niche, but when you've been around long enough, you know these 'niche' ideas can sometimes hatch golden eggs for investors....

Continue Reading
Bechtel's $1M Push for Wyoming's Skilled Trades Future

Updated Category News Views 204

Wyoming's Bid for Skilled Trades Revolution You’d think with all the talk about tech and white-collar jobs, we’ve forgotten the backbone that keeps the world ticking—skilled trades. Turns out, Bechtel hasn’t. The company just tossed a cool million at Wyoming's Laramie County Community College and Western Wyoming College. What’s that doing? It's jumpstarting...

Continue Reading
Trump Quotation Book Takes Unbiased Approach

Updated Category News Views 0

In the ever-evolving dance of political discourse, a new book strides onto the stage: Not My President, published by Palmetto Publishing. It’s a bold compilation of presidential utterances, capturing the words of Donald J. Trump in all their unvarnished glory. Stripped of analysis or comedic flair, each entry stands alone like a solitary figure at a cocktail party,...

Continue Reading

Top 5 Most Recently Viewed Articles

Empowering Tomorrow's Healers: Dr. Zarkadas' Scholarship

Updated Category News Views 116

Empowering Future Medical Leaders The Dr. Konstantinos Zarkadas Scholarship for Future Doctors is now open for applications. This scholarship invites undergraduate students committed to the field of medicine to apply for a prestigious award. The scholarship, which amounts to a one-time award of $1,000, aims to assist a deserving student who exemplifies both academic...

Continue Reading
Pharma Two B and Hepion Pharmaceuticals Merge for Growth

Updated Category News Views 47

Pharma Two B and Hepion Pharmaceuticals Announce Merger KIRYAT ONO, ISRAEL and EDISON, N.J. — Pharma Two B Ltd., a leading late-stage pharmaceutical company focused on treating Parkinson’s Disease, has officially announced its merger with Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA), which specializes in addressing chronic liver diseases. They have filed a registration...

Continue Reading
Applied Graphite Technologies Grants Stock Options to Team

Updated Category News Views 186

Applied Graphite Technologies' Recent Developments Applied Graphite Technologies Corporation (AGT) has made significant strides in its operations recently by granting 2,350,000 stock options to its consultants, directors, and officers. These options are set at an exercise price of $0.07, and they come with a five-year term, expiring on August 13, 2030. This move...

Continue Reading
Jefferson Solutions Group Sets Course for Strategic Growth

Updated Category News Views 7

Jefferson's Big Move: A Strategic Overhaul The winds of change are blowing over at Jefferson Solutions Group. This May, the company announced a heavy-duty strategic reorganization to better align with its astronomical ambitions for long-term growth. If you're the type that's got a soft spot for high-impact solutions and government gigs, pay attention, because this shift...

Continue Reading
Unbeatable Security Solutions for Your Home This Summer

Updated Category News Views 191

Unbeatable Security Solutions for Your Home This Summer As summer vacation approaches, ensuring the safety of your home becomes vital. Reolink, known for its innovative solutions in visual technology, has announced early Prime Day deals that will make securing your property both convenient and affordable. With these impressive offers, you can invest in top-rated security...

Continue Reading